2004 JAN 6 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals (AVN) announced that a commercial license agreement with Peregrine Pharmaceuticals, Inc., (PPHM) has been executed for an antibody Avanir produced for a cancer target in Peregrine's Vascular Targeting Agent (VTA) product pipeline.
The drug candidate is the product of a previous antibody research agreement between the companies that was designed to develop monoclonal antibodies for the treatment of solid tumor cancers. Under the terms of the agreement, Avanir has received a license fee and may receive a milestone payment and a royalty on sales upon successful development and commercialization of the …
No comments:
Post a Comment